Browsing Centre for Experimental Medicine and Rheumatology (EMR) by Author "Pratt, AG"
Now showing items 1-4 of 4
-
Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming
Cooles, FAH; Tarn, J; Lendrem, DW; Naamane, N; Lin, CMA; Millar, B; Maney, NJ; Anderson, AE; Thalayasingam, N; Diboll, J (2022) -
O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04-01) -
RANDOMISED, OPEN LABELLED CLINICAL TRIAL TO INVESTIGATE SYNOVIAL MECHANISMS DETERMINING RESPONSE: RESISTANCE TO RITUXIMAB VERSUS TOCILIZUMAB IN RA PATIENTS FAILING TNF INHIBITOR THERAPY
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04) -
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Rivellese, F; Nerviani, A; Giorli, G; Warren, L; Jaworska, E; Bombardieri, M; Lewis, MJ; Humby, F; Pratt, AG; Filer, A (2023-11-01)Background: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare ...